graph EGM comparisons
nivolumab alonetitlepembrolizumab alonetitlepembrolizumab (10mg/kg)titleatezolizumab plus SoCtitleatezolizumab plus cometinibtitlepembrolizumab plus SoCtitlenivolumab followed by ipilimumabtitlepembrolizumab (10mg/kg) 2 weekstitlepembrolizumab (2mg/kg)titleplacebo plus SoCtitleplacebotitleIpilimumab (10 mg/kg)titleipilimumab followed by nivolumabtitleipilimumab alonetitledacarbazinetitleStandard of Care (SoC)titleCheckMate 067 (N vs I ; all population), 2015 NCT01844505 mML - L1 - all population 316/315CheckMate 064, 2016 NCT01783938 mML - L1 - all population 68/70IMspire-150 (BRAF mutant), 2020 NCT02908672 mML - L1 - BRAF mutant 256/258IMspire-170, 2020 NCT03273153 mML - L1 - BRAF wild 222/224CheckMate 066, 2015 NCT01721772 mML - L1 - BRAF wild 210/208CheckMate 037, 2015 NCT01721746 mML - L2 - all population 272/133KEYNOTE-006 (3 week), 2015 NCT01866319 mML - L2 - all population 277/278KEYNOTE-002 (10 mg/kg), 2015 NCT01704287 mML - L2 - all population 181/179KEYNOTE-006 (2 week), 2015 NCT01866319 mML - L2 - all population 279/278KEYNOTE-002 (2 mg/kg), 2015 NCT01704287 mML - L2 - all population 180/179KEYNOTE-022, 2019 NCT02130466 mML - L2 - BRAF mutant 60/60CheckMate 238, 2017 NCT02388906 mML - NA - all population 453/453IMMUNED (N vs P ; all population), 2020 NCT02523313 mML - NA - all population 59/52KEYNOTE 054 (all population), 2018 NCT02362594 mML - NA - all population 514/505KEYNOTE 054 (PDL1>1%), 2018 NCT02362594 mML - NA - PDL1 positive 428/425

Pathology:  mML - L1 - all population;   mML - L1 - BRAF mutant;   mML - L1 - BRAF wild;   mML - L2 - all population;   mML - L2 - BRAF mutant;   mML - NA - all population;   mML - NA - PDL1 positive; 

mML - L1 - all populationmML - L1 - BRAF mutantmML - L1 - BRAF wildmML - L2 - all populationmML - L2 - BRAF mutantmML - NA - all populationmML - NA - PDL1 positive
CheckMate 067 (N vs I ; all population), 2015CheckMate 064, 2016IMspire-150 (BRAF mutant), 2020IMspire-170, 2020CheckMate 066, 2015CheckMate 037, 2015KEYNOTE-006 (3 week), 2015KEYNOTE-002 (10 mg/kg), 2015KEYNOTE-006 (2 week), 2015KEYNOTE-002 (2 mg/kg), 2015KEYNOTE-022, 2019CheckMate 238, 2017IMMUNED (N vs P ; all population), 2020KEYNOTE 054 (all population), 2018KEYNOTE 054 (PDL1>1%), 2018
nivolumab alone5T1T1T1T1T1
pembrolizumab alone2T0T1T1
pembrolizumab (10mg/kg)2T1T1
atezolizumab plus SoC1T1
atezolizumab plus cometinib1T1
pembrolizumab plus SoC1T1
nivolumab followed by ipilimumab1T1
pembrolizumab (10mg/kg) 2 weeks1T1
pembrolizumab (2mg/kg)1T1
placebo plus SoC0T0T0
placebo0T0T0T0
Ipilimumab (10 mg/kg)0T0
ipilimumab followed by nivolumab0T0
ipilimumab alone0T0T0T0
dacarbazine0T0
Standard of Care (SoC)0T0T0T0